Navigation Links
BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections
Date:7/6/2008

BD GeneOhm(TM) Cdiff Assay Submitted for FDA Clearance

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the CE marking of the BD GeneOhm(TM) Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection (CDI). It is the first CDI diagnostic test that offers sensitivity, simplicity and speed in one test procedure. BD has also submitted this assay to the U.S. Food and Drug Administration for clearance.

CE marked under the European In Vitro Diagnostics Directive for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. It is the only CDI diagnostic test that combines high assay sensitivity with a rapid turnaround time of less than two hours, facilitating earlier appropriate treatment of patients suffering from CDI and earlier implementation of infection control interventions to prevent transmission of Clostridium difficile to other patients. Until now, rapid diagnosis of CDI has been difficult since traditional methods consist of immunoassays, which lack sufficient sensitivity, and traditional "gold standard" tissue culture cytotoxicity methods, which are difficult to perform and require several days to yield results.

"The BD GeneOhm Cdiff assay provides a simple and rapid stool test with excellent sensitivity and specificity that allows same-day identification of toxigenic Clostridium difficile," said Thomas Davis, M.D., Ph.D., Professor, Pathology and Laboratory Medicine, Clarian Pathology Laboratory. "This test should improve patient care because it effectively
'/>"/>

SOURCE BD-Becton Dickinson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
(Date:2/26/2015)... SOUTH BEND, Ind. , Feb. 26, 2015 /PRNewswire/ ... to announce an agreement with Bank of America (NYSE: ... for consumers nationwide to receive financing of the revolutionary ... accessible vehicle, designed from the ground up to provide ... users. Approved applicants can use their loan to purchase ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... -- One of the best ways to encourage ... is to use a personalized approach, according to ... new study shows that simple, personalized interventions that ... improve colorectal cancer screening rates in primary care ...
... starting experiencing sounds as bodily sensations , , MONDAY, Sept. ... experienced sounds as bodily sensations after suffering a small ... the brain processes sensory signals and fixes itself when ... sound after suffering a stroke that only affected part ...
... Longs Drugs,(NYSE: LDG ) announced its flu immunization ... help residents of those communities remain,healthy and combat the annual ... to better meet its customers, needs. -- Longs Drugs ... beginning in October through the middle of ...
... MOUNT VERNON, Wash., Sept. 24 PreViser ... risk and disease analysis,software that enhances treatment ... a simultaneous release of a new corporate ... *(LOGO: http://www.Send2Press.com/mediaboom/07-0924-Previser_72dpi.jpg ) PreViser,s ...
... procedures, both surgical,and nonsurgical, have risen in popularity ... shows such as "Extreme Makeover." And, of course, ... "Nip/Tuck." Nearly 11.5 million cosmetic procedures were ... the American Society for Aesthetic Plastic,Surgery (ASAPS). ...
... websites with its newest category ... ... Great Consumer Driven Health Plan Websites, ... Conference in Philadelphia, the recognition,of the Nation,s Top 20 ... of data using the Healthcare Market Guide, and a,syndicated ...
Cached Medicine News:Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2Health News:Study Offers Insights Into Sensory Perceptions 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software 2Health News:Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 3
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Medicine Products: